The primary objective of this observational study is to investigate the Quality of Life and the perception of Crohn's disease patients who are in stable disease control and on stable subcutaneous ustekinumab treatment, when they are being switched from reference ustekinumab product (Stelara) to the ustekinumab biosimilar medicinal product Uzpruvo.